ArticleThe New England journal of medicine2017
Abiraterone in Metastatic Prostate Cancer.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.The Journal of urology · 2021Trial
- [Oligometastatic hormone-sensitive prostate cancer: when can less be more?]Urologie (Heidelberg, Germany) · 2026Review
- Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR.Mini reviews in medicinal chemistry · 2024Review
- Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies.Exploration of targeted anti-tumor therapy · 2024Review
- Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer.JAMA network open · 2021Article
- Article
- Whole-genome and enzymatic analyses of an androstenedione-producing Mycobacterium strain with residual phytosterol-degrading pathways.Microbial cell factories · 2020Article
- Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.Nature reviews. Urology · 2020Review
- Conceptual review of key themes in treating prostate cancer in older adults.Journal of geriatric oncology · 2020Review
- Projected estimates of cancer in Canada in 2020.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Article
- LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer.Frontiers in oncology · 2020Article
- Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.Cancer medicine · 2019Article
- Recent Advances in Prostate Cancer Treatment and Drug Discovery.International journal of molecular sciences · 2018Review
- Article
- Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations.Therapeutics and clinical risk management · 2018Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29069563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.